Modality
Radioligand
MOA
PD-1i
Target
RET
Pathway
PD-1/PD-L1
Ewing SarcomaThymoma
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
~Mar 2017
→ ~Jun 2018
Phase 2
Sep 2018
→ Feb 2029
Phase 2Current
NCT07039311
2,450 pts·Thymoma
2019-01→2029-02·Active
NCT05920386
487 pts·Ewing Sarcoma
2018-09→2025-05·Not yet recruiting
2,937 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-05-1710mo agoPh3 Readout· Ewing Sarcoma
2026-09-075mo awayEMA Filing· Thymoma
2029-02-172.9y awayPh3 Readout· Thymoma
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2/3
Not yet…
P2/3
Active
Catalysts
Ph3 Readout
2025-05-17 · 10mo ago
Ewing Sarcoma
EMA Filing
2026-09-07 · 5mo away
Thymoma
Ph3 Readout
2029-02-17 · 2.9y away
Thymoma
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07039311 | Phase 2/3 | Thymoma | Active | 2450 | UPDRS |
| NCT05920386 | Phase 2/3 | Ewing Sarcoma | Not yet recr... | 487 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| Nidaratamab | Krystal Biotech | Preclinical | RET | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R |